Document is current
Any future updates will be listed below
-
Authors
Saraon, Punit
Snider, Jamie
Kalaidzidis, Yannis https://orcid.org/0000-0002-6137-1193
Wybenga-Groot, Leanne E.
Weiss, Konstantin
Rai, Ankit https://orcid.org/0000-0002-3732-3597
Radulovich, Nikolina
Drecun, Luka
Vučković, Nika
Vučetić, Adriana
Wong, Victoria
Thériault, Brigitte
Pham, Nhu-An
Park, Jin H.
Datti, Alessandro
Wang, Jenny
Pathmanathan, Shivanthy
Aboualizadeh, Farzaneh
Lyakisheva, Anna
Yao, Zhong
Wang, Yuhui
Joseph, Babu
Aman, Ahmed
Moran, Michael F.
Prakesch, Michael
Poda, Gennady
Marcellus, Richard
Uehling, David
Samaržija, Miroslav
Jakopović, Marko
Tsao, Ming-Sound
Shepherd, Frances A.
Sacher, Adrian
Leighl, Natasha
Akhmanova, Anna https://orcid.org/0000-0002-9048-8614
Al-awar, Rima
Zerial, Marino https://orcid.org/0000-0002-7490-4235
Stagljar, Igor https://orcid.org/0000-0002-5260-3327
-
Funding
Funding for this research was provided by:
Canadian Cancer Society Research Institute (703889)
Cancer Research Society (23235)
Consortium Québécois sur la Découverte du Médicament (CQDM) (Explore) and OCE (#23929) Genome Canada via Ontario Genomics
- License Information
-
More Information
Article History
Received: 18 October 2017
Accepted: 27 January 2020
First Online: 24 February 2020
Competing interests
: I.S., P.S. and J.S. (in conjunction with the University of Toronto) are listed as inventors on a patent (publication no. 20190091205) for the use of EMI1 (and structurally related analogs), midostaurin, gilteritinib and AZD7762 (and structurally related analogs) in the treatment of mutant EGFR-mediated NSCLC.
